within Pharmacolibrary.Drugs.ATC.J;

model J02AC04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.54,
    Cl             = 7.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.236,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.000585,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Posaconazole is a triazole antifungal agent approved for the prevention and treatment of invasive fungal infections caused by Aspergillus and Candida species in immunocompromised patients. It is used both for prophylaxis in patients at high risk for fungal infections and for treatment of ongoing invasive infections. Approved by FDA and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers (median age 26, range 18–45), single-dose pharmacokinetics of oral posaconazole suspension following 400 mg dose in the fed state.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Brüggemann, RJM (2020). Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> 80(7) 671–695. DOI:<a href=&quot;https://doi.org/10.1007/s40265-020-01306-y&quot;>10.1007/s40265-020-01306-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32323222/&quot;>https://pubmed.ncbi.nlm.nih.gov/32323222</a></p></li><li><p>Li, H, et al., &amp; Xie, S (2019). Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability. <i>Clinical drug investigation</i> 39(11) 1109–1116. DOI:<a href=&quot;https://doi.org/10.1007/s40261-019-00833-1&quot;>10.1007/s40261-019-00833-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31432392/&quot;>https://pubmed.ncbi.nlm.nih.gov/31432392</a></p></li><li><p>Mawby, DI, et al., &amp; Papich, MG (2016). Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration. <i>Journal of veterinary internal medicine</i> 30(5) 1703–1707. DOI:<a href=&quot;https://doi.org/10.1111/jvim.14523&quot;>10.1111/jvim.14523</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27425589/&quot;>https://pubmed.ncbi.nlm.nih.gov/27425589</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J02AC04;
